Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ANTI-COCCIDIAL DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ANTI-COCCIDIAL DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ANTI-COCCIDIAL DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
6 INDUSTRY INSIGHTS
7 EPIDEMIOLOGY
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 MARKET ACCESS
9.1 10-YEAR MARKET FORECAST
9.2 ANNUAL NEW FDA APPROVED DRUGS
9.3 DRUGS MANUFACTURER AND DEALS
9.4 MAJOR DRUG UPTAKE
9.5 CURRENT TREATMENT PRACTICES
9.6 IMPACT OF UPCOMING THERAPY
10 PIPELINE ANALYSIS
Company Name Product Name
xx xx
xx xx
xx xx
xx xx
xx xx
xx xx
11 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY TYPE
11.1 OVERVIEW
11.2 SYNTHETIC DRUGS
11.2.1 ROBENIDINE
11.2.1.1. MARKET VALUE (USD MILLION)
11.2.1.2. MARKET VOLUME (UNITS)
11.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.2 AMPROLIUM
11.2.2.1. MARKET VALUE (USD MILLION)
11.2.2.2. MARKET VOLUME (UNITS)
11.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.3 ETHOPABATE
11.2.3.1. MARKET VALUE (USD MILLION)
11.2.3.2. MARKET VOLUME (UNITS)
11.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.4 APRINOCID
11.2.4.1. MARKET VALUE (USD MILLION)
11.2.4.2. MARKET VOLUME (UNITS)
11.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.5 CLOPIDOL
11.2.5.1. MARKET VALUE (USD MILLION)
11.2.5.2. MARKET VOLUME (UNITS)
11.2.5.3. AVERAGE SELLING PRICE (USD)
11.2.6 DECOQUINATE
11.2.6.1. MARKET VALUE (USD MILLION)
11.2.6.2. MARKET VOLUME (UNITS)
11.2.6.3. AVERAGE SELLING PRICE (USD)
11.2.7 DICLAZURIL
11.2.7.1. MARKET VALUE (USD MILLION)
11.2.7.2. MARKET VOLUME (UNITS)
11.2.7.3. AVERAGE SELLING PRICE (USD)
11.2.8 DINITOLMIDE
11.2.8.1. MARKET VALUE (USD MILLION)
11.2.8.2. MARKET VOLUME (UNITS)
11.2.8.3. AVERAGE SELLING PRICE (USD)
11.2.9 HALOFUGINONE
11.2.9.1. MARKET VALUE (USD MILLION)
11.2.9.2. MARKET VOLUME (UNITS)
11.2.9.3. AVERAGE SELLING PRICE (USD)
11.2.10 DEQUINATE
11.2.10.1. MARKET VALUE (USD MILLION)
11.2.10.2. MARKET VOLUME (UNITS)
11.2.10.3. AVERAGE SELLING PRICE (USD)
11.2.11 NICARBAZIN
11.2.11.1. MARKET VALUE (USD MILLION)
11.2.11.2. MARKET VOLUME (UNITS)
11.2.11.3. AVERAGE SELLING PRICE (USD)
11.2.12 SULFONAMIDES
11.2.12.1. MARKET VALUE (USD MILLION)
11.2.12.2. MARKET VOLUME (UNITS)
11.2.12.3. AVERAGE SELLING PRICE (USD)
11.2.13 OTHER
11.3 POLYETHER ANTIBIOTICS OR IONOPHORES
11.3.1 MONOVALENT IONOPHORES
11.3.1.1. MONENSIN
11.3.1.1.1. MARKET VALUE (USD MILLION)
11.3.1.1.2. MARKET VOLUME (UNITS)
11.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.2. NARASIN
11.3.1.2.1. MARKET VALUE (USD MILLION)
11.3.1.2.2. MARKET VOLUME (UNITS)
11.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3. SALINOMYCIN
11.3.1.3.1. MARKET VALUE (USD MILLION)
11.3.1.3.2. MARKET VOLUME (UNITS)
11.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.4. OTHER
11.3.2 MONOVALENT GLYCOSIDIC IONOPHORES
11.3.2.1. MADURAMICIN
11.3.2.1.1. MARKET VALUE (USD MILLION)
11.3.2.1.2. MARKET VOLUME (UNITS)
11.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.2.2. SEMDURAMICIN
11.3.2.2.1. MARKET VALUE (USD MILLION)
11.3.2.2.2. MARKET VOLUME (UNITS)
11.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.2.3. OTHER
11.3.3 DIVALENT IONOPHORES
11.3.3.1. LASALOCID
11.3.3.1.1. MARKET VALUE (USD MILLION)
11.3.3.1.2. MARKET VOLUME (UNITS)
11.3.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.3.2. OTHER
11.4 COMBINATION ANTI-COCCIDIAL DRUGS
11.4.1 NICARBAZIN/NARASIN
11.4.1.1. MARKET VALUE (USD MILLION)
11.4.1.2. MARKET VOLUME (UNITS)
11.4.1.3. AVERAGE SELLING PRICE (USD)
11.4.2 CLOPIDOL/ METHYL BENZOQUATE
11.4.2.1. MARKET VALUE (USD MILLION)
11.4.2.2. MARKET VOLUME (UNITS)
11.4.2.3. AVERAGE SELLING PRICE (USD)
11.4.3 OTHER
11.5 VACCINES
11.5.1 COCCIVAC-B
11.5.2 COCCIVACT
11.5.3 PARACOX-5
11.5.4 OTHER
11.6 OTHERS
12 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY ANIMAL TYPE
12.1 OVERVIEW
12.2 LIVESTOCK
12.2.1 CATTLE
12.2.2 SHEEP & GOATS
12.2.3 SWINE
12.2.4 OTHERS
12.3 POULTRY
12.3.1 CHICKENS
12.3.1.1. BROILERS
12.3.1.2. LAYERS
12.3.2 TURKEYS
12.3.3 DUCKS
12.3.4 OTHERS
12.4 FISH
12.5 OTHERS
13 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 BRANDED
13.2.1 MAXIBAN
13.2.2 LERBEK
13.2.3 DECCOX
13.2.4 AMPROL
13.2.5 CORID
13.2.6 CLINACOX
13.2.7 AVATEC
13.2.8 MONTEBAN
13.2.9 COBAN
13.2.10 OTHER
13.3 GENERICS
14 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 POWDERS
14.2.2 GRANULES
14.2.3 LIQUIDS
14.3 INJECTION
14.3.1 INTRAMUSCULARLY
14.3.2 SUBCUTANEOUSLY
14.4 OTHER
15 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY END USER
15.1 OVERVIEW
15.2 VETERINARY HOSPITALS
15.3 VETERINARY CARE
15.4 HOG PRODUCTION FARM
15.5 LIVESTOCK FARMS
15.6 POULTRY FARMS
15.7 OTHERS
16 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL PHARMACY
16.3.1 HOSPITAL ASSOCIATED PHARMACY
16.3.2 DRUG STORE
16.3.3 ONLINE PHARMACY
16.3.4 OTHER
16.4 OTHERS
17 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, BY GEOGRAPHY
18.1 GLOBAL ANTI-COCCIDIAL DRUGS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.1.1 NORTH AMERICA
18.1.1.1. U.S.
18.1.1.2. CANADA
18.1.1.3. MEXICO
18.1.2 EUROPE
18.1.2.1. GERMANY
18.1.2.2. U.K.
18.1.2.3. ITALY
18.1.2.4. FRANCE
18.1.2.5. SPAIN
18.1.2.6. RUSSIA
18.1.2.7. SWITZERLAND
18.1.2.8. TURKEY
18.1.2.9. BELGIUM
18.1.2.10. NETHERLANDS
18.1.2.11. DENMARK
18.1.2.12. SWEDEN
18.1.2.13. POLAND
18.1.2.14. NORWAY
18.1.2.15. FINLAND
18.1.2.16. REST OF EUROPE
18.1.3 ASIA-PACIFIC
18.1.3.1. JAPAN
18.1.3.2. CHINA
18.1.3.3. SOUTH KOREA
18.1.3.4. INDIA
18.1.3.5. SINGAPORE
18.1.3.6. THAILAND
18.1.3.7. INDONESIA
18.1.3.8. MALAYSIA
18.1.3.9. PHILIPPINES
18.1.3.10. AUSTRALIA
18.1.3.11. NEW ZEALAND
18.1.3.12. VIETNAM
18.1.3.13. TAIWAN
18.1.3.14. REST OF ASIA-PACIFIC
18.1.4 SOUTH AMERICA
18.1.4.1. BRAZIL
18.1.4.2. ARGENTINA
18.1.4.3. PERU
18.1.4.4. REST OF SOUTH AMERICA
18.1.5 MIDDLE EAST AND AFRICA
18.1.5.1. SOUTH AFRICA
18.1.5.2. EGYPT
18.1.5.3. BAHRAIN
18.1.5.4. UNITED ARAB EMIRATES
18.1.5.5. KUWAIT
18.1.5.6. OMAN
18.1.5.7. QATAR
18.1.5.8. SAUDI ARABIA
18.1.5.9. REST OF MEA
18.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
19 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, SWOT AND DBMR ANALYSIS
20 GLOBAL ANTI-COCCIDIAL DRUGS MARKET, COMPANY PROFILE
20.1 IMPEXTRACO NV
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPEMNTS
20.2 VETOQUINOL
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPEMNTS
20.3 PHIBRO ANIMAL HEALTH CORPORATION
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPEMNTS
20.4 HUVEPHARMA
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPEMNTS
20.5 VIRBAC
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPEMNTS
20.6 MERCK & CO.,INC
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPEMNTS
20.7 ZOETIS
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPEMNTS
20.8 ELANCO
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPEMNTS
20.9 CEVA
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPEMNTS
20.1 HIPRA
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPEMNTS
20.11 HUVEPHARMA
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPEMNTS
20.12 AURORA PHARMACEUTICAL, INC.
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPEMNTS
20.13 BOEHRINGER INGELHEIM LTD
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPEMNTS
20.14 CHINA ANIMAL HUSBANDRY GROUP
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPEMNTS
20.15 BAYER AG
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPEMNTS
20.16 BIOPROPERTIES PTY LTD
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPEMNTS
20.17 KEMIN INDUSTRIES, INC
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPEMNTS
20.18 QILU ANIMAL HEALTH PRODUCTS CO., LTD.
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPEMNTS
20.19 VENKYS INDIA
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPEMNTS
20.2 VETBIOCHEM INDIA PRIVATE LIMITED
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPEMNTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
